Immune manipulation of advanced breast cancer: An interpretative model of the relationship between immune system and tumor cell biology

Medicinal Research Reviews

Volumn 29, Issue 3, 2009, Pages 436-471

  Nicolini, Andrea ^a   Carpi, Angelo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Advanced breast cancer; Immunotherapy; Tumor biology

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BETA INTERFERON; BEVACIZUMAB; CAPECITABINE; CYTOKINE; DEATH RECEPTOR; EPIRUBICIN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; MEDROXYPROGESTERONE ACETATE; MELATONIN; PACLITAXEL; PROSTAGLANDIN E2; RETINOL PALMITATE; STAT3 PROTEIN; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; VASCULOTROPIN;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE MARROW CELL; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CELL FUNCTION; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; INNATE IMMUNITY; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; T LYMPHOCYTE ACTIVATION; TH2 CELL; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR IMMUNOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CYTOKINES; FEMALE; HUMANS; IMMUNE SYSTEM;

EID: 66149134453     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20143     Document Type: Review

References (294)

1. Nyström L, Rutqvist LE, Wall S, Lindgren A, Lindqvist M, Rydén S, Andersson I, Bjurstam N, Fagerberg G, Frisell J. Breast cancer screening with mammography: Overview of Swedish randomised trials. Lancet 1993;341:973-978. Erratum in: Lancet 1993 ;342:1372.
2. Kerlikowske K, Miglioretti DL, Buist DS, Walker R, Carney PA. National Cancer Institute- Sponsored Breast Cancer Surveillance Consortium. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 2007;99:1335-1339. Epub August 14, 2007. Erratum in: J Natl Cancer Inst 2007;99:1493.
3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
4. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007;608:1-22.
5. Nicolini A, Giardino R, Carpi A, Ferrari P, Anselmi L, Colosimo S, Conte M, Fini M, Giavaresi G, Berti P, Miccoli P. Metastatic breast cancer: An updating. Biomed Pharmacother 2006;60:548-556. Epub August 28, 2006.
6. Chia SKL, Speers C, Kang A, D'Yachova Y, Malfair Taylor S, Barnett J et al. The impact of new chemotherapeutic and hormonal agents on the survival of women with metastatic breast cancer (MBC) in a population based cohort. ASCO Proceedings 2003, Chicago, IL, May 31-June 3. p 89.
7. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-2676.
8. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
9. Nicolini A, Carpi A, Rossi G. Cytokines in breast cancer. Cytokine Growth Factor Rev 2006;17:325-337.
10. Fleming GF, Meropol NJ, Rosner GL, Hollis DR, Carson, 3rd WE, Caligiuri M, Mortimer J, Tkaczuk K, Parihar R, Schilsky RL, Ratain MJ. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: Report of cancer and leukemia group B 9661. Clin Cancer Res 2002;8:3718-3727. Erratum in: Clin Cancer Res 2003;9:1573.
11. Burns LJ, Weisdorf DJ, DeFor TE, Repka TL, Ogle KM, Hummer C, Miller JS. Enhancement of the anti-tumour activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer. Exp Hematol 2000;28:352.
12. Colucci G, Gebbia V, Giotta F, Pandolfo G, Testa A, Cannata G. High-dose epirubicin (EPI) with or without interleukin-2 (IL-2) in metastatic breast carcinoma: A phase III study of the Southern Italy Oncology Group. ASCO Proceedings, Denver, Co, May 17-20. p. 149.
13. Parihar R, Nadella P, Lewis A, Jensen R, De Hoff C, Dierksheide JE, VanBuskirk AM, Magro CM, Young DC, Shapiro CL, Carson WE 3rd. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: Analysis of sustained interferon gamma production in a subset of patients. Clin Cancer Res 2004;10:5027-5037.
14. Kornek G, Reiner A, Sagaster P, Stierer M, Mayer A, Ludwig H. Effect of interferon alpha-2a on hormone receptor status in patients with advanced breast cancer. Cancer Invest 1999;17:189-194.
15. Ozzello L, Habif DV, De Rosa CM, Cantell K. Cellular events accompanying regression of skin recurrences of breast carcinomas treated with intralesional injections of natural interferons alpha and gamma. Cancer Res 1992;52:4571-4581.
16. Sica G, Iacopino F, Lama G, Amadori D, Baroni M, Lo Sardo F. Steroid receptor enhancement by natural interferon-beta in advanced breast cancer. Eur J Cancer 1993;29:329-333.
17. Miglietta L, Repetto L, Gardin G, Amoroso D, Giudici S, Naso C. Tamoxifen and alpha interferon in advanced breast cancer. J Chemother 1991;3:383-386.
18. Seymour L, Bezwoda WR. Interferon plus tamoxifen treatment for advanced breast cancer: In vivo biologic effects of two growth modulators. Br J Cancer 1993;68:352-356.
19. Macheledt JE, Buzdar AU, Hortobagyi GN, Frye DK, Gutterman JU, Holmes FA. Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer. Breast Cancer Res Treat 1991;18:165-170.
20. Recchia F, Frati L, Rea S, Torchio P, Sica G. Minimal residual disease in metastatic breast cancer: Treatment with IFN-beta, retinoids, and tamoxifen. J Interferon Cytokine Res 1998;18:41-47.
21. Buzzi F, Brugia M, Rossi G, Giustini L, Scoponi C, Sica G. Combination of beta-interferon and tamoxifen as a new way to overcome clinical resistance to tamoxifen in advanced breast cancer. Anticancer Res 1992;12:869-871.
22. Buzzi E, Brugia M, Trippa F, Rossi G, Trivisonne R, Giustini L, Pinaglia D, Capparella V, Sica G. Natural interferon-beta and tamoxifen in hormone-resistant patients with advanced breast cancer. Anticancer Res 1995;15:2187-2190.
23. Repetto L, Giannessi PG, Campora E, Pronzato P, Vigani A, Naso C, Spinelli I, Conte PF, Rosso R. Tamoxifen and interferon-beta for the treatment of metastatic breast cancer. Breast Cancer Res Treat 1996;39:235-238.
24. Recchia F, Rea S, De Filippis S, Rosselli M, Corrao G, Gulino A, Sica G. Beta-interferon, retinoids and tamoxifen combination in advanced breast cancer. Clin Ter 1998;149:203-208.
25. Peretz T, Kaplan-DeNour A, Baider L, Hubert A, Stephanos S, Barak V. Combination of interferon and tamoxifen for patients with advanced breast cancer and negative oestrogen receptors. Breast 1997; 6:190-193.
26. Barak V, Kalickman I, Nisman B, Farbstein H, Fridlender ZG, Baider L, Kaplan A, Stephanos S, Peretz T. Changes in cytokine production of breast cancer patients treated with interferons. Cytokine 1998;10:977-983.
27. Nicolini A, Carpi A. Advanced breast cancer: An update and controversies on diagnosis and therapy. Biomed Pharmacother 2003;57:439-446.
28. Olivotto IA, Chua B, Allan SJ, Speers CH, Chia S, Ragaz J. Long-term survival of patients with supraclavicular metastases at diagnosis of breast cancer. J Clin Oncol 2003;21:851-854.
29. Pierga JY, Asselain B, Jouve M, Dieras V, Carton M, Laurence V, Girre V, Beuzeboc P, Palangié T, Dorval T, Pouillart P. Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy. Cancer 2001;91:1079-1089.
30. Yamamoto N, Watanabe T, Katsumata N, Omuro Y, Ando M, Fukuda H, Takue Y, Narabayashi M, Adachi I, Takashima S. Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol 1998;16:2401-2408.
31. Sledge Jr GW, Hu P, Falkson G, Tormey D, Abeloff M. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 2000;18:262-266.
32. Nicolini A, Carpi A. Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: An exploratory trial. Biomed Pharmacother 2005;59:253-263.
33. Nicolini A, Carpi A, Rossi G. An immunotherapy schedule in endocrine-dependent metastatic breast cancer: Correlation between clinical course and immunologic parameters. J Immunother 2005;28:276-279.
34. Revillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998;34:791-808.
35. Volpi A, Nanni O, De Paola F, Granato AM, Mangia A, Monti F, Schittulli F, De Lena M, Scarpi E, Rosetti P, Monti M, Gianni L, Amadori D, Paradiso A. HER-2 expression and cell proliferation: Prognostic markers in patients with node-negative breast cancer. J Clin Oncol 2003;21:2708-2712.
36. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001;19:2722-2730.
37. Nicolini A, Campani D, Miccoli P, Spinelli C, Carpi A, Menicagli M, Ferrari P, Gadducci G, Rossi G, Fini M, Giavaresi G, Bonazzi V, Giardino R. Vascular endothelial growth factor (VEGF) and other common tissue prognostic indicators in breast cancer: A case-control study. Int J Biol Markers 2004;19:275-281.
38. Ignoffo RJ. Overview of bevacizumab: A new cancer therapeutic strategy targeting vascular endothelial growth factor. Am J Health Syst Pharm 2004;61:S21-S26.
39. Miller K, Wang M, Gralow J. A randomised phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 2005; 94:S6 (abs 3).
40. Ehrlich P. In: Himmelweit F, editor. The collected papers of Paul Ehrlich, vol II. London: Pergamon Press; 1957. p 559.
41. Burnet FM. Cancer: A biological approach. Br Med J 1957;1:779-841.
42. Old LJ. Cancer immunology: The search for specificity - G. H. A. Clowes Memorial lecture. Cancer Res 1981;41:361-375.
43. Traversari C, van der Bruggen P, Van den Eynde B, Hainaut P, Lemoine C, Ohta N, Old L, Boon T. Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes. Immunogenetics 1992;35:145-152.
44. Sahin U, Türeci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995;92:11810-11813.
45. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-1647.
46. Coulie PG, Brichard V, Van Pel A, Wölfel T, Schneider J, Traversari C, Mattei S, De Plaen E, Lurquin C, Szikora JP, Renauld JC, Boon T. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994;180:35-42.
47. Parmiani G, De Filippo A, Novellino L, Castelli C. Unique human tumour antigens: Immunobiology and use in clinical trials. J Immunol 2007;178:1975-1979.
48. Boon T, van der Bruggen P. Human tumour antigens recognized by T lymphocytes. J Exp Med 1996;183:725-729.
49. Old LJ, Chen YT. New paths in human cancer serology. J Exp Med 1998;187:1163-1167.
50. Fecher LA, Cummings SD, Keefe MJ, Alani RM. Toward a molecular classification of melanoma. J Clin Oncol 2007;25:1606-1620.
51. Basil CF, Zhao Y, Zavaglia K, Jin P, Panelli MC, Voiculescu S, Mandruzzato S, Lee HM, Seliger B, Freedman RS, Taylor PR, Hu N, Zanovello P, Marincola FM, Wang E. Common cancer biomarkers. Cancer Res 2006;66:2953-2961.
52. Kaliss N, Borges PRF, Day ED. The survival and metastatic spread of homografts of mouse tumours in mice pretreated with lyophilized tissue and cortisone. Cancer Res 1953;14:210-219.
53. Flexner S, Jobling JW. Restraint and promotion of tumour growth. Proc Soc Exp Biol Med 1907;5:16-18.
54. Prehn RT. The immune reaction as a stimulator of tumour growth. Science 1972;176:170-171.
55. Prehn RT, Prehn LM. The autoimmune nature of cancer. Cancer Res 1987;47:927-932.
56. Stutman O. Immunodepression and malignancy. Adv Cancer Res 1975;22:261-422.
57. Moller G, Moller E. The concept of immunological surveillance against neoplasia. Transplant Rev 1976;28:3-16.
58. Melief CJM, Schwartz MA. Immunocompetence and malignancy. In: Becker F, editor. Cancer: A comprehensive treatise, vol 1. New York: Plenum Press; 1975. p 121.
59. Flanagan SP. 'Nude', a new hairless gene with pleiotropic effects in the mouse. Genet Res 1966;8:295-309.
60. Pantelouris EM. Absence of thymus in a mouse mutant. Nature 1968;217:370-371.
61. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD. Demonstration of an interferon gamma-dependent tumour surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998;95:7556-7561.
62. Street SE, Cretney E, Smyth MJ. Perforin and interferon-gamma activities independently control tumour initiation, growth, and metastasis. Blood 2001;97:192-197.
63. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002;20:323-370.
64. van den Broek ME, Kagi D, Ossendorp F, Toes R, Vamvakas S, Lutz WK, Melief CJ, Zinkernagel RM, Hengartner H. Decreased tumour surveillance in perforin-deficient mice. J Exp Med 1996;184:1781-1790.
65. Shinkai Y, Rathbun G, Lam KP, Oltz EM, Stewart V, Mendelsohn M, Charron J, Datta M, Young F, Stall AM, Alt AW. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 1992;68:855-867.
66. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-1111.
67. Street SE, Trapani JA, MacGregor D, Smyth MJ. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med 2002;196:129-134.
68. Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, Taniguchi M, Kawano T, Pelikan SB, Crowe NY, Godfrey DI. Differential tumour surveillance by natural killer (NK) and NKT cells. J Exp Med 2000;191:661-668.
69. Gresser I, Bourali C, Lévy JP, Fontaine-Brouty-Boyé D, Thomas MT. Increased survival in mice inoculated with tumour cells and treated with interferon preparations. Proc Natl Acad Sci USA 1969;63:51-57.
70. Gresser I, Maury C, Brouty-Boyé D. Mechanism of the antitumour effect of interferon in mice. Nature 1972;239:167-168.
71. Reid LM, Minato N, Gresser I, Holland J, Kadish A, Bloom BR. Influence of anti-mouse interferon serum on the growth and metastasis of tumour cells persistently infected with virus and of human prostatic tumours in athymic nude mice. Proc Natl Acad Sci USA 1981;78:1171-1175.
72. Sheehan KC, Lai KS, Dunn GP, Bruce AT, Diamond MS, Heutel JD, Dungo-Arthur C, Carrero JA, White JM, Hertzog PJ, Schreiber RD. Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. J Interferon Cytokine Res 2006;26:804-819.
73. Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, Diamond MS, Koebel CM, Arthur C, White JM, Schreiber RD. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005;6:722-729. Epub June 12, 2005. Erratum in: Nat Immunol 2005;6:852.
74. Penn I. Posttransplant malignancies. Transplant Proc 1999;31:1260-1262.
75. Birkeland SA, Storm HH, Lamm LU, Barlow L, Blohme I, Forsberg B, Eklund B, Fjeldborg O, Friedberg M, Frodin L, Glattre E, Halvorsen S, Holm NV, Jakobsen A, Jorgesen SE, Ladefoged J, Lindholm T, Lundgren G, Pukkala E. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer 1995;60:183-189.
76. Sheil AGR. In: Morris PJ, editor. Kidney transplantation. Philadelphia: Saunders; 2001. pp 558-570.
77. Boshoff C, Weiss R. AIDS-related malignancies. Nat Rev Cancer 2002;2:373-382.
78. Sheil AG. Cancer after transplantation. World J Surg 1986;10:389-396.
79. Penn I. Malignant melanoma in organ allograft recipients. Transplantation 1996;61:274-278.
80. Penn I. Sarcomas in organ allograft recipients. Transplantation 1995;60:1485-1491.
81. Clark Jr WH, Elder DE, Guerry 4th D, Braitman LE, Trock BJ, Schultz D, Synnestvedt M, Halpern AC. Model predicting survival in stage I melanoma based on tumour progression. J Natl Cancer Inst 1989;81:1893-1904.
82. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H. CD81 T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998;58:3491-3494.
83. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: From immunosurveillance to tumour escape. Nat Immunol 2002;3:991-998.
84. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-360.
85. van der Vliet HJ, Molling JW, von Blomberg BM, Nishi N, Kölgen W, van den Eertwegh AJ, Pinedo HM, Giaccone G, Scheper RJ. The immunoregulatory role of CD1d-restricted natural killer T cells in disease. Clin Immunol 2004;112:8-23.
86. Godfrey DI, Kronenberg M. Going both ways: Immune regulation via CD1d-dependent NKT cells. J Clin Invest 2004;114:1379-1388.
87. Ebert EC, Groh V. Dissection of spontaneous cytotoxicity by human intestinal intraepithelial lymphocytes: MIC on colon cancer triggers NKG2D-mediated lysis through Fas ligand. Immunology 2008;124:33-41.
88. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6:24-37.
89. Moser B, Brandes M. Gammadelta T cells: An alternative type of professional APC. Trends Immunol 2006;27:112-118.
90. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000;96:384-392.
91. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumour-associated expression and recognition by tumour-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 1999;96:6879-6884.
92. Vetter CS, Groh V, thor Straten P, Spies T, Bröcker EB, Becker JC. Expression of stress-induced MHC class I related chain molecules on human melanoma. J Invest Dermatol 2002;118:600-605.
93. Jinushi M, Takehara T, Tatsumi T, Kanto T, Groh V, Spies T, Kimura R, Miyagi T, Mochizuki K, Sasaki Y, Hayashi N. Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int J Cancer 2003;104:354-361.
94. Groh V, Steinle A, Bauer S, Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 1998;279:1737-1740.
95. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002;419:734-738.
96. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumourigenesis. Cell 1996;86:353-364.
97. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumour immunosurveillance and immunotherapy. Nat Immunol 2001;2:293-299.
98. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045.
99. Yokoyama WM. Now you see it, now you don't! Nat Immunol 2000;1:95-97.
100. Cerwenka A, Bakker AB, McClanahan T, Wagner J, Wu J, Phillips JH, Lanier LL. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 2000;12:721-727.
101. Bromberg JF, Horvath CM, Wen Z, Schreiber RD, Darnell Jr JE, Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci USA 1996;93:7673-7678.
102. Kumar A, Commane M, Flickinger TW, Horvath CM, Stark GR. Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science 1997;278:1630-1632.
103. Luster AD, Ravetch JV. Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J Exp Med 1987;166:1084-1097.
104. Liao F, Rabin RL, Yannelli JR, Koniaris LG, Vanguri P, Farber JM. Human Mig chemokine: Biochemical and functional characterization. J Exp Med 1995;182:1301-1314.
105. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007;117:1195-1203.
106. Pardoll D. Does the immune system see tumours as foreign or self? Annu Rev Immunol 2003;21:807-839. Epub December 19, 2001.
107. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137-148.
108. Ichim CV. Revisiting immunosurveillance and immunostimulation: Implications for cancer immunotherapy. J Transl Med 2005;3:8.
109. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004;4:665-674.
110. Romagnani S. Regulatory T cells: Which role in the pathogenesis and treatment of allergic disorders? Allergy 2006;61:3-14.
111. Khong HT, Restifo NP. Natural selection of tumour variants in the generation of "tumour escape" phenotypes. Nat Immunol 2002;3:999-1005.
112. Waldner M, Schimanski CC, Neurath MF. Colon cancer and the immune system: The role of tumour invading T cells. World J Gastroenterol 2006;12:7233-7238.
113. Seliger B, Cabrera T, Garrido F, Ferrone S. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 2002;12:3-13.
114. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumours from T-cell recognition: Molecular mechanisms and functional significance. Adv Immunol 2000;74:181-273.
115. Rouas-Freiss N, Moreau P, Menier C, LeMaoult J, Carosella ED. Expression of tolerogenic HLA-G molecules in cancer prevents antitumour responses. Semin Cancer Biol 2007;17:413-421. Epub July 17, 2007.
116. Dutta N, Gupta A, Mazumder DN, Banerjee S. Down-regulation of locus-specific human lymphocyte antigen class I expression in Epstein-Barr virus-associated gastric cancer: Implication for viral-induced immune evasion. Cancer 2006;106:1685-1693.
117. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE, Herlyn M. A tumourigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005;65:9328-9337.
118. Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ, Tahan SR. Increased expression of stem cell markers in malignant melanoma. Mod Pathol 2007;20:102-107.
119. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumourigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-3988. Epub March 10, 2003. Erratum in: Proc Natl Acad Sci USA 2003;100:6890.
120. Zhou G, Lu Z, McCadden JD, Levitsky HI, Marson AL. Reciprocal changes in tumour antigenicity and antigen-specific T cell function during tumour progression. J Exp Med 2004;200:1581-1592.
121. Schreiber H, Wu TH, Nachman J, Kast WM. Immunodominance and tumour escape. Semin Cancer Biol 2002;12:25-31.
122. Landowski TH, Qu N, Buyuksal I, Painter JS, Dalton WS. Mutations in the Fas antigen in patients with multiple myeloma. Blood 1997;90:4266-4270.
123. Gronbaek K, Straten PT, Ralfkiaer E, Ahrenkiel V, Andersen MK, Hansen NE, Zeuthen J, Hou-Jensen K, Guldberg P. Somatic Fas mutations in non-Hodgkin's lymphoma: Association with extranodal disease and autoimmunity. Blood 1998;92:3018-3024.
124. Shin MS, Park WS, Kim SY, Kim HS, Kang SJ, Song KY, Park JY, Dong SM, Pi JH, Oh RR, Lee JY, Yoo NJ, Lee SH. Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma. Am J Pathol 1999;154:1785-1791.
125. Medema JP, de Jong J, Peltenburg LT, Verdegaal EM, Gorter A, Bres SA, Franken KL, Hahne M, Albar JP, Melief CJ, Offringa R. Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumours. Proc Natl Acad Sci USA 2001;98:11515-11520.
126. Hersey P, Zhang XD. How melanoma cells evade trail-induced apoptosis. Nat Rev Cancer 2001;1:142-150.
127. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, Green DR, Kratzke RA. Human lung carcinomas express Fas ligand. Cancer Res 1997;57:1007-1012.
128. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumour immune escape. Science 1996;274:1363-1366.
129. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996;184:1075-1082.
130. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumour cells-A mechanism of immune evasion? Nat Med 1996;2:1361-1366.
131. Zaks TZ, Chappell DB, Rosenberg SA, Restifo NP. Fas-mediated suicide of tumour-reactive T cells following activation by specific tumour: Selective rescue by caspase inhibition. J Immunol 1999;162:3273-3279.
132. Lenardo MJ. The molecular regulation of lymphocyte apoptosis. Semin Immunol 1997;9:1-5.
133. Andreola G, Rivoltini L, Castelli C, Huber V, Perego P, Deho P, Squarcina P, Accornero P, Lozupone F, Lugini L, Stringaro A, Molinari A, Arancia G, Gentile M, Parmiani G, Fais S. Induction of lymphocyte apoptosis by tumour cell secretion of FasL-bearing microvesicles. J Exp Med 2002;195:1303-1316.
134. Huber V, Fais S, Iero M, Lugini L, Canese P, Squarcina P, Zaccheddu A, Colone M, Arancia G, Gentile M, Seregni E, Valenti R, Ballabio G, Belli F, Leo E, Parmiani G, Rivoltini L. Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: Role in immune escape. Gastroenterology 2005;128:1796-1804.
135. Valenti R, Huber V, Filipazzi P, Pilla L, Sovena G, Villa A, Corbelli A, Fais S, Parmiani G, Rivoltini L. Human tumour-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res 2006;66:9290-9298.
136. Iero M, Valenti R, Huber V, Filipazzi P, Parmiani G, Fais S, Rivoltini L. Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ 2008;15:80-88. Epub October 12, 2007.
137. DeSimone PA, East R, Powell Jr RD. Phagocytic tumour cell activity in oat cell carcinoma of the lung. Hum Pathol 1980;11:535-539.
138. Fujii M, Ishii Y, Wakabayashi T, Itoyanagi N, Hagiwara K, Saito M, Takahashi M. Cytologic diagnosis of male breast cancer with nipple discharge. A case report. Acta Cytol 1986;30:21-24.
139. Kojima S, Sekine H, Fukui I, Ohshima H. Clinical significance of "cannibalism" in urinary cytology of bladder cancer. Acta Cytol 1998;42:1365-1369.
140. Lugini L, Matarrese P, Tinari A, Lozupone F, Federici C, Iessi E, Gentile M, Luciani F, Parmiani G, Rivoltini L, Malorni W, Fais S. Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. Cancer Res 2006;66:3629-3638.
141. Darnell Jr JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264:1415-1421.
142. Darnell Jr JE. STATs and gene regulation. Science 1997;277:1630-1635.
143. Bromberg J, Darnell Jr JE. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000;19:2468-2473.
144. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000;19:2474-2488.
145. Darnell Jr JE. Studies of IFN-induced transcriptional activation uncover the Jak-Stat pathway. J Interferon Cytokine Res 1998;18:549-554.
146. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998;67:227-264.
147. Ihle JN. The Stat family in cytokine signaling. Curr Opin Cell Biol 2001;13:211-217.
148. Reddy EP, Korapati A, Chaturvedi P, Rane S. IL-3 signaling and the role of Src kinases, JAKs and STATs: A covert liaison unveiled. Oncogene 2000;19:2532-2547.
149. Blume-Jensen P, Hunter T. Oncogenic kinase signaling. Nature 2001;411:355-365.
150. Yu H, Jove R. The STATs of cancer-New molecular targets come of age. Nat Rev Cancer 2004;4:97-105.
151. Parsons JT, Parsons SJ. Src family protein tyrosine kinases: Cooperating with growth factor and adhesion signaling pathways. Curr Opin Cell Biol 1997;9:187-192.
152. Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene 2000;19:5636-5642.
153. Danial NN, Rothman P. JAK-STAT signaling activated by Abl oncogenes. Oncogene 2000;19:2523-2531.
154. Lin TS, Mahajan S, Frank DA. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 2000;19:2496-2504.
155. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, Dalton W, Jove R, Pardoll D, Yu H. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumour cells. Nat Med 2004;10:48-54. Epub December 21, 2003. Erratum in: Nat Med 2004;10:209.
156. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP. Production of vascular endothelial growth factor by human tumours inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096-1103. Erratum in: Nat Med 1996;2:1267.
157. Yang AS, Lattime EC. Tumour-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res 2003;63:2150-2157.
158. Cheng F, Wang HW, Cuenca A, Huang M, Ghansah T, Brayer J, Kerr WG, Takeda K, Akira S, Schoenberger SP, Yu H, Jove R, Sotomayor EM. A critical role for Stat3 signaling in immune tolerance. Immunity 2003;19:425-436.
159. Fuchs EJ, Matzinger P. Is cancer dangerous to the immune system? Semin Immunol 1996;8:271-280.
160. Matzinger P. Introduction to the series. Danger model of immunity. Scand J Immunol 2001;54:2-3.
161. Karin M. NF-kappaB and cancer: Mechanisms and targets. Mol Carcinog 2006;45:355-361.
162. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001;1:135-145.
163. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002;109 :S81-96.
164. Park JM, Greten FR, Wong A, Westrick RJ, Arthur JS, Otsu K, Hoffmann A, Montminy M, Karin M. Signaling pathways and genes that inhibit pathogen-induced macrophage apoptosis-CREB and NF-kappaB as key regulators. Immunity 2005;23:319-329.
165. Werner S, Beer HD, Mauch C, Luscher B, Werner S. The Mad1 transcription factor is a novel target of activin and TGF-beta action in keratinocytes: Possible role of Mad1 in wound repair and psoriasis. Oncogene 2001;20:7494-7504.
166. Covert MW, Leung TH, Gaston JE, Baltimore D. Achieving stability of lipopolysaccharide-induced NF-kappaB activation. Science 2005;309:1854-1857.
167. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4(1)CD25(1) T cells with regulatory properties from human blood. J Exp Med 2001;193:1303-1310.
168. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC. Prevalence of regulatory T cells is increased in peripheral blood and tumour microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-2761.
169. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH. Regulatory CD4(+)CD25(+) T cells in tumours from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766-4772.
170. Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: Possible involvement of regulatory T cells in disease progression. Cancer 2003;98:1089-1099.
171. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25(1)CD4(1) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002;3:135-142.
172. McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, Collins M, Byrne MC. CD4(1)CD25(1) immunoregulatory T cells: Gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002;16:311-323.
173. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000;192:1213-1222.
174. Shevach EM. CD4+ CD25+ suppressor T cells: More questions than answers. Nat Rev Immunol 2002;2:389-400.
175. Green EA, Choi Y, Flavell RA. Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: Highly potent regulators of diabetes that require TRANCE-RANK signals. Immunity 2002;16:183-191.
176. Thornton AM, Donovan EE, Piccirillo CA, Shevach EM. Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol 2004;172:6519-6523.
177. de la Rosa M, Rutz S, Dorninger H, Scheffold A. Interleukin-2 is essential for CD4+CD25+ regulatory T cell function. Eur J Immunol 2004;34:2480-2488.
178. Curotto de Lafaille MA, Lino AC, Kutchukhidze N, Lafaille JJ. CD25-T cells generate CD25+Foxp3+ regulatory T cells by peripheral expansion. J Immunol 2004;173:7259-7268.
179. Terabe M, Berzofsky JA. Immunoregulatory T cells in tumour immunity. Curr Opin Immunol 2004;16:157-162.
180. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006;107:2409-2414.
181. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005;6:1142-1151. Epub October 16, 2005. Erratum in: Nat Immunol 2006;7:427.
182. Yu P, Fu YX. Tumour-infiltrating T lymphocytes: Friends or foes? Lab Invest 2006;86:231-245.
183. Saito A, Narita M, Yokoyama A, Watanabe N, Tochiki N, Satoh N, Takizawa J, Furukawa T, Toba K, Fuse I, Aizawa Y, Shinada S, Takahashi M. Enhancement of anti-tumour cytotoxicity of expanded gammadelta T Cells by stimulation with monocyte-derived dendritic cells. J Clin Exp Hematop 2007;47:61-72.
184. Tokuyama H, Hagi T, Mattarollo SR, Morley J, Wang Q, Fai-So H, Moriyasu F, Nieda M, Nicol AJ. V gamma 9 V delta 2 T cell cytotoxicity against tumour cells is enhanced by monoclonal antibody drugs - Rituximab and trastuzumab. Int J Cancer 2008;122:2526-2534.
185. Abbas AK, Lichtman AH, editors. Cellular and molecular Immunology. Fifth edition. Milan: Masson; 2006. Italian version, chapter 5, pp 82-106.
186. Kaplan MH, Sun YL, Hoey T, Grusby MJ. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 1996;382:174-177.
187. Shimoda K, van Deursen J, Sangster MY, Sarawar SR, Carson RT, Tripp RA, Chu C, Quelle FW, Nosaka T, Vignali DA, Doherty PC, Grosveld G, Paul WE, Ihle JN. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 1996;380:630-633.
188. Bocek Jr P, Foucras G, Paul WE. Interferon gamma enhances both in vitro and in vivo priming of CD4+ T cells for IL-4 production. J Exp Med 2004;199:1619-1630.
189. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996;17:138-146.
190. Adler AJ, Marsh DW, Yochum GS, Guzzo JL, Nigam A, Nelson WG, Pardoll DM. CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells. J Exp Med 1998;187:1555-1564.
191. Chomarat P, Banchereau J, Davoust J, Palucka AK. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 2000;1:510-514.
192. Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ. MUC1 immunobiology: From discovery to clinical applications. Adv Immunol 2004;82:249-293.
193. Pardoll DM, Topalian SL. The role of CD4+ T cell responses in antitumour immunity. Curr Opin Immunol 1998;10:588-594.
194. Qin Z, Richter G, Schuler T, Ibe S, Cao X, Blankenstein T. B cells inhibit induction of T cell-dependent tumour immunity. Nat Med 1998;4:627-630.
195. Bronte V, Apolloni E, Cabrelle A, Ronca R, Serafini P, Zamboni P, Restifo NP, Zanovello P. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 2000;96:3838-3846.
196. Melani C, Chiodoni C, Forni G, Colombo MP. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 2003;102:2138-2145. Epub May 15, 2003.
197. Kusmartsev S, Gabrilovich DI. Inhibition of myeloid cell differentiation in cancer: The role of reactive oxygen species. J Leukoc Biol 2003;74:186-196.
198. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP, Gabrilovich DI. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000;6:1755-1766.
199. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI. Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer. J Immunol 2001;166:678-689.
200. Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE, Morris JC. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 2004;113:1515-1525.
201. Bronte V, Serafini P, Apolloni E, Zanovello P. Tumour-induced immune dysfunctions caused by myeloid suppressor cells. J Immunother 2001;24:431-446.
202. Serafini P, De Santo C, Marigo I, Cingarlini S, Dolcetti L, Gallina G, Zanovello P, Bronte V. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 2004;53:64-72. Epub October 30, 2003.
203. Kusmartsev S, Gabrilovich DI. Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother 2002;51:293-298. Epub April 24, 2002.
204. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004;4:941-952.
205. Baniyash M. TCR zeta-chain downregulation: Curtailing an excessive inflammatory immune response. Nat Rev Immunol 2004;4:675-687.
206. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: Recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006;16:53-65. Epub September 15, 2005.
207. Lang R, Patel D, Morris JJ, Rutschman RL, Murray PJ. Shaping gene expression in activated and resting primary macrophages by IL-10. J Immunol 2002;169:2253-2263.
208. Lin CS, Ho HC, Chen KC, Lin G, Nunes L, Lue TF. Intracavernosal injection of vascular endothelial growth factor induces nitric oxide synthase isoforms. Br J Urol Int 2002;89:955-960.
209. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004;64:6337-6343.
210. Cruz MT, Duarte CB, Gonc-alo M, Figueiredo A, Carvalho AP, Lopes MC. Granulocyte-macrophage colony-stimulating factor activates the transcription of nuclear factor kappa B and induces the expression of nitric oxide synthase in a skin dendritic cell line. Immunol Cell Biol 2001;79:590-596.
211. Dawn B, Xuan YT, Guo Y, Rezazadeh A, Stein AB, Hunt G, Wu WJ, Tan W, Bolli R. IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2. Cardiovasc Res 2004;64:61-71.
212. Leite-de-Moraes MC, Lisbonne M, Arnould A, Machavoine F, Herbelin A, Dy M, Schneider E. Ligand-activated natural killer T lymphocytes promptly produce IL-3 and GM-CSF in vivo: Relevance to peripheral myeloid recruitment. Eur J Immunol 2002;32:1897-1904.
213. Terabe M, Matsui S, Park JM, Mamura M, Noben-Trauth N, Donaldson DD, Chen W, Wahl SM, Ledbetter S, Pratt B, Letterio JJ, Paul WE, Berzofsky JA. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumour immunosurveillance: Abrogation prevents tumour recurrence. J Exp Med 2003;198:1741-1752.
214. Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD, Carbone DP, Paul WE, Berzofsky JA. NKT cell-mediated repression of tumour immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000;1:515-520.
215. Melero I, Bach N, Chen L. Costimulation, tolerance and ignorance of cytolytic T lymphocytes in immune responses to tumour antigens. Life Sci 1997;60:2035-2041.
216. Cantrell D. T cell antigen receptor signal transduction pathways. Annu Rev Immunol 1996;14:259-274.
217. Linsley PS, Clark EA, Ledbetter JA. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci USA 1990;87:5031-5035.
218. Azuma M, Ito D, Yagita H, Okumura K, Phillips JH, Lanier LL, Somoza C. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 1993;366:76-79.
219. Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo Jr VA, Lombard LA, Gray GS, Nadler LM. Cloning of B7-2: A CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 1993;262:909-911.
220. Wells AD, Walsh MC, Bluestone JA, Turka LA. Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy. J Clin Invest 2001;108:895-903.
221. Abken H, Hombach A, Heuser C, Kronfeld K, Seliger B. Tuning tumour-specific T-cell activation: A matter of costimulation?Trends Immunol 2002;23:240-245.
222. Toi M, Taniguchi T, Yamamoto Y, Kurisaki T, Suzuki H, Tominaga T. Clinical significance of the determination of angiogenic factors. Eur J Cancer 1996;32A:2513-2519.
223. Oyama T, Ran S, Ishida T, Nadaf S, Kerr L, Carbone DP, Gabrilovich DI. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 1998;160:1224-1232.
224. Abbas AK, Lichtman AH, editors. Cellular and molecular Immunology. Fifth edition. Milan: Masson; 2006. Italian version, chapter 11, pp 249-280.
225. Patel KB, Berd D, Mastrangelo MJ, Terai M, Sato T. Prognostic importance of interleukin-10 (IL-10) production by metastatic melanoma tissues from patients receiving autologous vaccine therapy. ASCO Proceedings 2002. Orlando, FL, May 18-21; p 432a, abs 1726.
226. Girolomoni G, Ricciardi-Castagnoli P. Dendritic cells hold promise for immunotherapy. Immunol Today 1997;18:102-104.
227. De Smedt T, Van Mechelen M, De Becker G, Urbain J, Leo O, Moser M. Effect of interleukin-10 on dendritic cell maturation and function. Eur J Immunol 1997;27:1229-1235.
228. Sharma S, Stolina M, Lin Y, Gardner B, Miller PW, Kronenberg M, Dubinett SM. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J Immunol 1999;163:5020-5028.
229. Ludewig B, Graf D, Gelderblom HR, Becker Y, Kroczek RA, Pauli G. Spontaneous apoptosis of dendritic cells is efficiently inhibited by TRAP (CD40-ligand) and TNF-alpha, but strongly enhanced by interleukin-10. Eur J Immunol 1995;25:1943-1950.
230. Carbone E, Terrazzano G, Ruggiero G, Zanzi D, Ottaiano A, Manzo C, Karre K, Zappacosta S. Recognition of autologous dendritic cells by human NK cells. Eur J Immunol 1999;29:4022-4029.
231. Yue FY, Dummer R, Geertsen R, Hofbauer G, Laine E, Manolio S, Burg G. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer 1997;71:630-637.
232. Salazar-Onfray F, Charo J, Petersson M, Freland S, Noffz G, Qin Z, Blankenstein T, Ljunggren HG, Kiessling R. Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumour cell lines expressing IL-10. J Immunol 1997;159:3195-3202.
233. Zeidler R, Eissner G, Meissner P, Uebel S, Tampe R, Lazis S, Hammerschmidt W. Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10. Blood 1997;90:2390-2397.
234. Huang M, Stolina M, Sharma S, Mao JT, Zhu L, Miller PW, Wollman J, Herschman H, Dubinett SM. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokinebalance in lymphocytes and macrophages: Up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998;58:1208-1216.
235. Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA. Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res 1992;52:6949-6952.
236. Doran T, Stuhlmiller H, Kim JA, Martin Jr EW, Triozzi PL. Oncogene and cytokine expression of human colorectal tumours responding to immunotherapy. J Immunother 1997;20:372-376.
237. Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S, Ito H, Nishimoto N, Yoshizaki K, Kishimoto T, Galle PR, Blessing M, Rose-John S, Neurath MF. TGF-beta suppresses tumour progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004;21:491-501.
238. Chen W, Frank ME, Jin W, Wahl SM. TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity 2001;14:715-725.
239. Fontana A, Frei K, Bodmer S, Hofer E, Schreier MH, Palladino Jr MA, Zinkernagel RM. Transforming growth factor-beta inhibits the generation of cytotoxic T cells in virus-infected mice. J Immunol 1989;143:3230-3234.
240. Morris DR, Kuepfer CA, Ellingsworth LR, Ogawa Y, Rabinovitch PS. Transforming growth factor-beta blocks proliferation but not early mitogenic signaling events in T-lymphocytes. Exp Cell Res 1989;185:529-534.
241. Stoeck M, Miescher S, MacDonald HR, Von Fliedner V. Transforming growth factors beta slow down cell-cycle progression in a murine interleukin-2 dependent T-cell line. J Cell Physiol 1989;141:65-73.
242. Brabletz T, Pfeuffer I, Schorr E, Siebelt F, Wirth T, Serfling E. Transforming growth factor beta and cyclosporin A inhibit the inducible activity of the interleukin-2 gene in T cells through a noncanonical octamer-binding site. Mol Cell Biol 1993;13:1155-1162.
243. Hoehn P, Goedert S, Germann T, Koelsch S, Jin S, Palm N, Ruede E, Schmitt E. Opposing effects of TGF-beta 2 on the Th1 cell development of naive CD4+ T cells isolated from different mouse strains. J Immunol 1995;155:3788-3793.
244. Sad S, Mosmann TR. Single IL-2-secreting precursor CD4 T cell can develop into either Th1 or Th2 cytokine secretion phenotype. J Immunol 1994;153:3514-3522.
245. Swain SL, Huston G, Tonkonogy S, Weinberg A. Transforming growth factor-beta and IL-4 cause helper T cell precursors to develop into distinct effector helper cells that differ in lymphokine secretion pattern and cell surface phenotype. J Immunol 1991;147:2991-3000.
246. Gorelik L, Constant S, Flavell RA. Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation. J Exp Med 2002;195:1499-1505.
247. Heath VL, Murphy EE, Crain C, Tomlinson MG, O'Garra A. TGF-beta1 down-regulates Th2 development and results in decreased IL-4-inducedSTAT6 activation and GATA-3 expression. Eur J Immunol 2000;30:2639-2649.
248. Gorelik L, Fields PE, Flavell RA. Cutting edge: TGF-beta inhibits Th type 2 development through inhibition of GATA-3 expression. J Immunol 2000;165:4773-4777.
249. Becker C, Fantini MC, Neurath MF. TGF-beta as a T cell regulator in colitis and colon cancer. Cytokine Growth Factor Rev 2006;17:97-106.
250. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signaling through the gp130/Jak/STAT pathway. Biochem J 1998;334:297-314.
251. Miller LJ, Kurtzman SH, Anderson K, Wang Y, Stankus M, Renna M, Lindquist R, Barrows G, Kreutzer DL. Interleukin-1 family expression in human breast cancer: Interleukin-1 receptor antagonist. Cancer Invest 2000;18:293-302.
252. Pantschenko AG, Pushkar I, Anderson KH, Wang Y, Miller LJ, Kurtzman SH, Barrows G, Kreutzer DL. The interleukin-1 family of cytokines and receptors in human breast cancer: Implications for tumour progression. Int J Oncol 2003;23:269-284.
253. Singer CF, Kronsteiner N, Hudelist G, Marton E, Walter I, Kubista M. Interleukin 1 system and sex steroid receptor expression in human breast cancer: Interleukin 1alpha protein secretion is correlated with malignant phenotype. Clin Cancer Res 2003;9:4877-4883.
254. Liu L, Gudas LJ. Retinoic acid induces expression of the interleukin-1beta gene in cultured normal human mammary epithelial cells and in human breast carcinoma lines. J Cell Physiol 2002;193:244-252.
255. Honma S, Shimodaira K, Shimizu Y, Tsuchiya N, Saito H, Yanaihara T, Okai T. The influence of inflammatory cytokines on estrogen production and cell proliferation in human breast cancer cells. Endocr J 2002;49:371-377.
256. Kurebayashi J. Regulation of interleukin-6 secretion from breast cancer cells and its clinical implications. Breast Cancer 2000;7:124-129.
257. Knupfer H, Schmidt R, Stanitz D, Brauckhoff M, Schonfelder M, Preiss R. CYP2C and IL-6 expression in breast cancer. Breast 2004;13:28-34.
258. Kovacs E. Investigation of interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R) and soluble gp130 (sgp130) in sera of cancer patients. Biomed Pharmacother 2001;55:391-396.
259. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: A review of the rationale and clinical evidence. Clin Cancer Res 2003;9:4653-4665.
260. Banks RE, Forbes MA, Patel PM, Storr M, Hallam S, Clarke D, Novick D, Ingham E, Bowmer C, Southgate J, Trejdosiewicz LK, Ilingworth J, Perren TJ, Selby PJ. Subcutaneous administration of recombinant glycosylated interleukin 6 in patients with cancer: Pharmacokinetics, pharmacodynamics and immunomodulatory effects. Cytokine 2000;12:388-396.
261. Vitolo D, Ciocci L, Ferrauti P, Tiboni F, Cicerone E, Gallo A, DeVincentiis M, Baroni CD. Interleukin-12-related cytokine gene expression in carcinomas of the breast, lung, and larynx: A study at tissue level. Cancer Detect Prev 2000;24:422-434.
262. Iacopetta B, Grieu F, Joseph D. The -174 G/C gene polymorphism in interleukin-6 is associated with an aggressive breast cancer phenotype. Br J Cancer 2004;90:419-422.
263. Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpe S, Vermeulen PB, Dirix LY. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 2004;10:7157-7162.
264. Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y, Abe A. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 2001;7:285-289.
265. Meng L, Zhou J, Sasano H, Suzuki T, Zeitoun KM, Bulun SE. Tumour necrosis factor alpha and interleukin 11 secreted by malignant breast epithelial cells inhibit adipocyte differentiation by selectively down-regulating CCAAT/enhancer binding protein alpha and peroxisome proliferator-activated receptor gamma: Mechanism of desmoplastic reaction. Cancer Res 2001;61:2250-2255.
266. Lichtner RB. Estrogen/EGF receptor interactions in breast cancer: Rationale for new therapeutic combination strategies. Biomed Pharmacother 2003;57:447-451.
267. Pietras RJ. Interactions between estrogen and growth factor receptors in human breast cancers and the tumour-associated vasculature. Breast J 2003;9:361-373.
268. Newton CJ, Buric R, Trapp T, Brockmeier S, Pagotto U, Stalla GK. The unliganded estrogen receptor (ER) transduces growth factor signals. J Steroid Biochem Mol Biol 1994;48:481-486.
269. Lee AV, Weng CN, Jackson JG, Yee D. Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endocrinol 1997;152:39-47.
270. Stewart AJ, Johnson MD, May FE, Westley BR. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem 1990;265:21172-21178.
271. Jechlinger M, Sommer A, Moriggl R, Seither P, Kraut N, Capodiecci P, Donovan M, Cordon-Cardo C, Beug H, Grunert S. Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest 2006;116:1561-1570.
272. Carvalho I, Milanezi F, Martins A, Reis RM, Schmitt F. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res 2005;7:R788-R795.
273. Bos R, van Diest PJ, de Jong JS, van der Groep P, van der Valk P, van der Wall E. Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology 2005;46:31-36.
274. Mattila MM, Tarkkonen KM, Seppanen JA, Ruohola JK, Valve EM, Harkonen PL. Androgen and fibroblast growth factor 8 (FGF8) downregulation of thrombospondin 1 (TSP1) in mouse breast cancer cells. Mol Cell Endocrinol 2006;253:36-43.
275. Vandermoere F, El Yazidi-Belkoura I, Adriaenssens E, Lemoine J, Hondermarck H. The antiapoptotic effect of fibroblast growth factor-2 is mediated through nuclear factor-kappaB activation induced via interaction between Akt and IkappaB kinase-beta in breast cancer cells. Oncogene 2005;24:5482-5491.
276. Seeger H, Wallwiener D, Mueck AO. Influence of stroma-derived growth factors on the estradiol-stimulated proliferation of human breast cancer cells. Eur J Gynaecol Oncol 2004;25:175-177.
277. Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, Pardoll D, Levitsky H. Induction of antigen-specific T cell anergy: An early event in the course of tumour progression. Proc Natl Acad Sci USA 1998;95:1178-1183.
278. Tzachanis D, Freeman GJ, Hirano N, van Puijenbroek AA, Delfs MW, Berezovskaya A, Nadler LM, Boussiotis VA. Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. Nat Immunol 2001;2:1174-1182.
279. Gravis G, Viens P, Vey N, Blaise D, Stoppa AM, Olive D, Maraninchi D. Pilot study of immunotherapy with interleukin-2 after autologous stem cell transplantation in advanced breast cancers. Anticancer Res 2000;20:3987-3991.
280. Weber J, Yang JC, Topalian SL, Parkinson DR, Schwartzentruber DS, Ettinghausen SE, Gunn H, Mixon A, Kim H, Cole D, Levin R, Rosenberg SA. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol 1993;11:499-506.
281. Nguyen van Binh P, Duc HT. Analyses and perspectives in cancer immunotherapy. Biomed Pharmacother 2006;60:621-628.
282. Rosenberg SA. Progress in the development of immunotherapy for the treatment of patients with cancer. J Intern Med 2001;250:462-475.
283. Nicolini A, Carpi A, Tarro G. Biomolecular markers of breast cancer. Front Biosci 2006;11:1818-1843.
284. Osborne CK. Interactions of tamoxifen with cytotoxic chemotherapy for breast cancer. In: Jordan VC, editor. Long-term tamoxifen treatment for breast cancer. Madison: The University of Wisconsin Press; 1994. pp 181-196.
285. O'Brian CA, Liskamp RM, Solomon DH, Weinstein IB. Triphenylethylenes: A new class of protein kinase C inhibitors. J Natl Cancer Inst 1986;76:1243-1246.
286. Clarke R, van den Berg HW, Murphy RF. Reduction of the membrane fluidity of human breast cancer cells by tamoxifen and 17 beta-estradiol. J Natl Cancer Inst 1990;82:1702-1705.
287. Greenberg DA, Carpenter CL, Messing RO. Calcium channel antagonist properties of the antineoplastic antiestrogen tamoxifen in the PC12 neurosecretory cell line. Cancer Res 1987;47:70-74.
288. Friedl A, Jordan VC, Pollak M. Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy. Eur J Cancer 1993;29A:1368-1372.
289. Wolf DM, Gottardis MM, Jordan V. Tamoxifen-resistant growth. In: Craig Jordan V, editor. Long-term tamoxifen treatment for breast cancer. Madison: The University of Wisconsin Press; 1994. pp 199-217.
290. Osborne CK. Receptors. In: Harris JR, Hellman S, Henderson IC, Kinne DW, editors. Breast diseases, 2nd edition. Philadelphia: J.B. Lippincott Company; 1995. pp 301-325.
291. Bezwoda WR, Meyer K. Effect of alpha-interferon, 17 beta-estradiol, and tamoxifen on estrogen receptor concentration and cell cycle kinetics of MCF 7 cells. Cancer Res 1990;50:5387-5391.
292. Adams JM, Cory S. The Bcl-2 protein family: Arbiters of cell survival. Science 1998;281:1322-1326.
293. Nicolini A, Carpi A, Ferrari P, Rossi G. Immunotherapy prolongs the serum CEA-TPA-CA15.3 lead time at the metastatic progression in endocrine-dependent breast cancer patients: A retrospective longitudinal study. Cancer Lett 2008;263:122-129. Epub January 31, 2008.
294. Nicolini A, Carpi A, Rossi G. Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy. Cancer Lett 2007;251:330-338.